Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Januar 2026 18:12 ET | Quelle: Direct Meds

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

Direct Meds reviews best GLP-1 weight loss shot prescription pathways for 2026 as oral semaglutide and injectable formats expand patient access.
07. Januar 2026 20:05 ET | Quelle: Direct Meds

Best Oral Peptides for Weight Loss: Injectable vs Sublingual vs Daily Pill – Direct Meds Consumer Analysis

January 2026 consumer analysis compares oral Wegovy, compounded sublingual semaglutide, and tirzepatide drops across pricing and access formats.
06. Januar 2026 21:10 ET | Quelle: Direct Meds

Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access

Oral Wegovy launch expands GLP-1 format options as Direct Meds telehealth platform compares FDA-approved vs compounded semaglutide pricing structures.
30. Dezember 2025 20:57 ET | Quelle: Direct Meds

Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study

Industry analysis examines how patients verify telehealth GLP-1 platforms after FDA oral semaglutide approval. Direct Meds included as case study.
26. Dezember 2025 23:34 ET | Quelle: Direct Meds

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Analysis examines Direct Meds GLP-1 medications platform as LegitScript-certified telehealth option for compounded semaglutide and tirzepatide access.